Why might high levels of branched-chain amino acids be linked with type II diabetes risk in obesity?

Created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

Diagram illustrating metabolism with two sections: anabolic reaction on the left shows energy used to build larger molecules from smaller ones, while catabolic reaction on the right shows larger molecules breaking down into smaller molecules with energy released. — Metabolomics In anabolic reactions, a cell uses energy to combine small molecules into larger molecules. In catabolic reactions, molecules are broken down, and energy is released.

The premise that high levels of branched-chain amino acids (BCAAs)—specifically leucine, isoleucine, and valine—are linked to type II diabetes risk in obesity is supported by metabolomic research identifying these as distinct metabolic signatures of disease susceptibility.1

The elevation of these amino acids in individuals prone to these conditions is not attributed to a single cause but is likely driven by a combination of the following factors:

Dietary Intake: Excess consumption of protein can contribute to higher circulating levels of these amino acids.1
Genetic Factors: Variations in the genes responsible for encoding catabolic enzymes may impair the body's ability to break down BCAAs efficiently.1
Microbiome Influence: Alterations in the metabolism of gut microbes may influence the systemic levels of these metabolites.1

These findings highlight the complexity of metabolic health, where specific patterns of circulating metabolites serve as indicators of increased risk for cardiovascular disease and diabetes, necessitating a nuanced approach to understanding how small molecules participate in diverse biochemical pathways.1